Pulmonx Co. (NASDAQ:LUNG) Receives $12.75 Average Price Target from Analysts

Pulmonx Co. (NASDAQ:LUNG) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $12.75.

A number of analysts recently commented on LUNG shares. Stifel Nicolaus dropped their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Wells Fargo & Company decreased their price target on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Finally, Citigroup reissued a “neutral” rating and issued a $7.50 price objective (down previously from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th.

Insider Activity

In other Pulmonx news, General Counsel David Aaron Lehman sold 5,497 shares of Pulmonx stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $6.19, for a total value of $34,026.43. Following the transaction, the general counsel now owns 197,851 shares in the company, valued at $1,224,697.69. This trade represents a 2.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Geoffrey Beran Rose sold 4,376 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.18, for a total value of $27,043.68. Following the sale, the insider now owns 291,057 shares of the company’s stock, valued at approximately $1,798,732.26. The trade was a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,873 shares of company stock valued at $324,070 in the last 90 days. 5.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently added to or reduced their stakes in the company. 272 Capital LP acquired a new position in shares of Pulmonx in the 3rd quarter valued at about $25,000. nVerses Capital LLC purchased a new position in Pulmonx in the third quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Pulmonx in the second quarter valued at approximately $37,000. SG Americas Securities LLC acquired a new position in Pulmonx during the third quarter valued at approximately $102,000. Finally, Hsbc Holdings PLC purchased a new stake in Pulmonx during the second quarter worth approximately $93,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Performance

Shares of LUNG opened at $6.16 on Wednesday. Pulmonx has a 12-month low of $5.46 and a 12-month high of $14.84. The stock has a market cap of $243.25 million, a P/E ratio of -4.19 and a beta of 0.69. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $6.49 and a two-hundred day moving average of $6.84.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same quarter in the prior year, the company earned ($0.39) EPS. As a group, research analysts predict that Pulmonx will post -1.53 EPS for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.